Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ4CSX)

Drug Name

Rezafungin Drug Info

Synonyms

CD-101; CD101; SP-3025; CHEMBL3989945; HY-108009; CS-0027142; J3.555.717B; J3.599.425D; (4R,5R)-N2-[4-(4'-Pentoxy-1,1'-biphenyl-4-yl)benzoyl]-5-[2-(trimethylaminio)ethoxy]-4-hydroxy-cyclo[L-Orn*-[(3R)-3-methyl-L-Ser-]-[(4R)-4-hydroxy-L-Pro-]-2-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-L-Gly-[(3R)-3-methyl-L-Ser-]-[(3S,4S)-3-hydroxy-4-methyl-L-Pro-]-]

Indication

Disease Entry	ICD 11	Status	REF
Candidiasis	1F23	Approved	[1]

Cross-matching ID

PubChem CID: 78318119
TTD Drug ID: DMQ4CSX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fungal 1,3-beta-glucan synthase (Fung GSC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caspofungin	DMGQIPT	Candidiasis	1F23	Approved	[3]
Micafungin	DM6Y3AN	Aspergillosis	1F20	Approved	[4]
Ibrexafungerp	DMK1IPV	Vulvovaginal Candidiasis	1F23.10	Approved	[5]
Anidulafungin	DM8QM5U	Aspergillosis	1F20	Approved	[6]
L-733560	DMYZPJU	Aspergillosis	1F20	Terminated	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fungal 1,3-beta-glucan synthase (Fung GSC2)	TT0SFXH	FKS2_YEAST	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217417.
2	Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
5	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.
6	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
7	Discovery of Novel Antifungal (1,3)--d-Glucan Synthase Inhibitors